Journal article
Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021
CC Chang, CC Blyth, SCA Chen, A Khanina, CO Morrissey, JA Roberts, KA Thursky, LJ Worth, MA Slavin
Internal Medicine Journal | Published : 2021
DOI: 10.1111/imj.15585
Abstract
This article introduces the fourth update of the Australian and New Zealand consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting. These guidelines are comprised of nine articles as presented in this special issue of the Internal Medicine Journal. This introductory chapter outlines the rationale for the current update and the steps taken to ensure implementability in local settings. Given that 7 years have passed since the previous iteration of these guidelines, pertinent contextual changes that impacted guideline content and recommendations are discussed, including the evolution of invasive fungal disease (IFD) de..
View full abstractGrants
Awarded by Pfizer
Funding Acknowledgements
All work was performed gratis by the steering committee, contributing authors and members of ALLG, ASID, ANZCHOG, MOGA and HSANZ. M. A. Slavin (Leadership 2, APP1173791), C. C. Blyth (Emerging Leadership, APP1173163), C. C. Chang (Early Career fellowship, APP1092960) and J. A. Roberts (Practitioner fellowship, APP1117065) are funded by the Australian National Health and Medical Research Council (NHMRC). Meetings and administration were supported by the National Centre for Infections in Cancer Centre of Research Excellence (NCIC CRE, GNT1116876). ASID provided funding for Dr Candice O'Sullivan and Angelica Papanicolaou, professional medical writers from Wellmark Pty Ltd., Melbourne (a healthcare communications agency), to provide writing assistance and format the manuscripts for journal submission. This special issue of the journal was funded by Wiley through unrestricted educational grants from Gilead Sciences and Pfizer. These companies had no input into the scope or content of the guidelines, nor access to drafts prior to publication. Throughout the period of guideline development, Wellmark had no commercial affiliations with any of these companies and did not produce communications for any antifungal brands mentioned in these guidelines.